Imugene Ltd (ASX: IMU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imugene Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$57.87 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
324.76 million
Earnings per share
-0.225
Dividend per share
N/A
Year To Date Return
-49.32%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imugene Ltd (ASX: IMU)
Latest News
Share Market News
Here are the top 10 ASX 200 shares today
Earnings Results
Net loss doubles in FY22, so what's with the Imugene share price today?
Share Market News
Here are the top 10 ASX 200 shares today
Healthcare Shares
The Imugene share price has tumbled 18% since the company's last update. What's happening?
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the 3 most heavily traded ASX 200 shares on Wednesday
Share Gainers
Why Graincorp, Imugene, iSelect, and Mayne Pharma shares are racing higher
Healthcare Shares
Imugene share price lifts 11% on clinical trial update
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Why Appen, Imugene, OZ Minerals, and Paradigm shares are charging higher
Share Market News
Here are the top 10 ASX 200 shares today
Healthcare Shares
Up 22% in a month, can the Imugene share price extend its rally?
Frequently Asked Questions
-
Imugene does not pay dividends at this stage.
-
Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.
IMU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Imugene Ltd
Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.
The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.
The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu.
Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.
IMU Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Mar 2026 | $0.19 | $-0.01 | -5.26% | 652,914 | $0.19 | $0.19 | $0.18 |
| 12 Mar 2026 | $0.19 | $0.00 | 0.00% | 2,561,478 | $0.19 | $0.20 | $0.18 |
| 11 Mar 2026 | $0.19 | $-0.04 | -17.39% | 4,543,023 | $0.24 | $0.24 | $0.18 |
| 09 Mar 2026 | $0.23 | $0.00 | 0.00% | 468,174 | $0.23 | $0.24 | $0.23 |
| 06 Mar 2026 | $0.24 | $-0.01 | -4.08% | 523,611 | $0.25 | $0.25 | $0.24 |
| 05 Mar 2026 | $0.25 | $0.01 | 4.17% | 859,897 | $0.24 | $0.25 | $0.24 |
| 04 Mar 2026 | $0.24 | $0.04 | 19.51% | 2,341,253 | $0.21 | $0.25 | $0.21 |
| 03 Mar 2026 | $0.21 | $-0.01 | -4.65% | 711,113 | $0.22 | $0.22 | $0.21 |
| 02 Mar 2026 | $0.22 | $-0.02 | -8.33% | 3,192,247 | $0.24 | $0.24 | $0.21 |
| 27 Feb 2026 | $0.24 | $0.00 | 0.00% | 217,576 | $0.24 | $0.25 | $0.24 |
| 26 Feb 2026 | $0.24 | $0.00 | 0.00% | 341,600 | $0.24 | $0.25 | $0.24 |
| 25 Feb 2026 | $0.24 | $-0.02 | -7.84% | 1,500,612 | $0.25 | $0.26 | $0.24 |
| 24 Feb 2026 | $0.26 | $0.01 | 4.00% | 251,306 | $0.25 | $0.26 | $0.25 |
| 23 Feb 2026 | $0.25 | $0.00 | 0.00% | 998,265 | $0.26 | $0.27 | $0.25 |
| 20 Feb 2026 | $0.25 | $0.01 | 4.08% | 522,359 | $0.25 | $0.25 | $0.24 |
| 19 Feb 2026 | $0.25 | $-0.01 | -4.00% | 460,147 | $0.26 | $0.26 | $0.24 |
| 18 Feb 2026 | $0.25 | $0.01 | 4.08% | 627,515 | $0.25 | $0.26 | $0.25 |
| 17 Feb 2026 | $0.25 | $-0.01 | -3.92% | 467,598 | $0.25 | $0.25 | $0.25 |
| 16 Feb 2026 | $0.26 | $0.00 | 0.00% | 378,167 | $0.26 | $0.26 | $0.25 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 17 Dec 2025 | Lesley Russell | Exercise | 14,706 | $4,705 |
Conversion of securities. 88,235 RSU
|
| 17 Dec 2025 | Kim Drapkin | Exercise | 14,706 | $4,705 |
Conversion of securities. 88,235 RSU
|
| 17 Dec 2025 | Lesley Russell | Issued | 14,706 | $4,705 |
Conversion of securities.
|
| 17 Dec 2025 | Jakob Dupont | Exercise | 14,706 | $4,705 |
Conversion of securities. 88235 RSU
|
| 17 Dec 2025 | Kim Drapkin | Issued | 14,706 | $4,705 |
Conversion of securities.
|
| 17 Dec 2025 | Jakob Dupont | Issued | 14,706 | $4,705 |
Conversion of securities.
|
| 15 Dec 2025 | Paul Hopper | Issued | 124,054 | $39,077 |
Employee Share Ownership Plan. 260,320 rights, As per announcement on 19-12-2025
|
| 15 Dec 2025 | Jakob Dupont | Issued | 29,411 | $9,264 |
Employee Share Ownership Plan. 102941 RSU
|
| 15 Dec 2025 | Leslie (Mi Ok) Chong | Issued | 751,621 | $236,760 |
Employee Share Ownership Plan. 1,518,441 Rights
|
| 15 Dec 2025 | Lesley Russell | Issued | 29,411 | $9,264 |
Employee Share Ownership Plan. 1,02,941 RSU
|
| 15 Dec 2025 | Kim Drapkin | Issued | 29,411 | $9,264 |
Employee Share Ownership Plan. 1,02,941 RSU
|
| 21 Jul 2025 | Leslie (Mi Ok) Chong | Issued | 170,405 | $62,197 |
Conversion of securities.
|
| 21 Jul 2025 | Leslie (Mi Ok) Chong | Exercise | 170,405 | $62,197 |
Conversion of securities. 51,877,139 Rights, As per annoucnement on 23-07-2025
|
| 21 Jul 2025 | Paul Hopper | Exercise | 28,688 | $10,471 |
Conversion of securities. 136,266 Rights
|
| 21 Jul 2025 | Paul Hopper | Issued | 28,688 | $10,471 |
Conversion of securities.
|
| 11 Jul 2025 | Lesley Russell | Exercise | 7,353 | $3,125 |
Conversion of securities. 73,530 RSu
|
| 11 Jul 2025 | Kim Drapkin | Buy | 7,353 | $3,125 |
Conversion of securities.
|
| 11 Jul 2025 | Lesley Russell | Buy | 7,353 | $3,125 |
Conversion of securities.
|
| 11 Jul 2025 | Kim Drapkin | Exercise | 7,353 | $3,125 |
Conversion of securities.
|
| 11 Jul 2025 | Jakob Dupont | Buy | 7,353 | $3,125 |
Conversion of securities.
|
| 11 Jul 2025 | Jakob Dupont | Exercise | 7,353 | $3,125 |
Conversion of securities. 73,530 RSU
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Leslie (Mi Ok) Chong | Chief Executive OfficerManaging Director | Nov 2016 |
Ms Chong joined the Group in September 2015 from the oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in clinical and department development in oncology.
|
| Mr Paul Alex Hopper | Executive ChairmanExecutive Director | Dec 2013 |
Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered several therapeutic areas with a particular emphasis on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States.
|
| Dr Lesley Russell | Non-Executive Director | Apr 2019 |
Dr Russell is a haematologist/oncologist and has over 25 years of experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in several therapeutic areas including haematology/oncology and has had multiple new drug approvals with both FDA and European Medicines Agency. Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a Member of the Risk Committee.
|
| Dr Jakob Dupont | Non-Executive Director | Sep 2022 |
Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and numerous preclinical programs. He is a Member of the Risk Committee.
|
| Ms Kim Drapkin | Non-Executive Director | Jun 2023 |
Ms Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. In addition to Imugene, Ms Drapkin currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) where she chairs the audit committee and is a member of the compensation committee and LENZ Therapeutics (NASDAQ: LENZ) where she is a member of the compensation and governance committees. Most recently, Ms Drapkin was CEO and a board member at Graphite Bio where she led the strategic alternatives process. Prior to that, Ms Drapkin was CFO at Jounce Therapeutics since its inception, playing a key role in building Jounce's financial infrastructure. She is Chair of the Risk Committee.
|
| Mr Darren Keamy | Chief Financial OfficerCompany Secretary | Mar 2025 |
-
|
| Darren Keamy | Chief Financial Officer |
-
|
|
| Darren Keamy | Chief Financial OfficerCompany Secretary |
-
|
|
| John Byon | Chief Medical Officer |
-
|
|
| Bradley Glover | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 18,911,753 | 6.56% |
| Citicorp Nominees Pty Limited | 12,481,773 | 4.33% |
| HSBC Custody Nominees (Australia) Limited | 10,894,815 | 3.78% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 9,326,372 | 3.23% |
| BNP Paribas Noms Pty Ltd | 7,242,189 | 2.51% |
| Mann Family | 6,799,883 | 2.36% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 3,919,518 | 1.36% |
| Dr Nicholas Smith | 3,470,589 | 1.20% |
| Netwealth Investments Limited <Wrap Services A/C> | 3,334,273 | 1.16% |
| Buttonwood Nominees Pty Ltd | 2,802,209 | 0.97% |
| HSBC Custody Nominees (Australia) Limited Gsco Eca | 2,678,213 | 0.93% |
| Mi Ok Chong | 2,618,782 | 0.91% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 2,319,579 | 0.80% |
| UBS Nominees Pty Ltd | 1,839,876 | 0.64% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 1,736,771 | 0.60% |
| Finclear Services Pty Ltd <Superhero Securities A/C> | 1,478,363 | 0.51% |
| BNP Paribas Nominees Pty Ltd <Barclays> | 1,421,895 | 0.49% |
| Dr Larry Jordan | 1,401,765 | 0.49% |
| Mr Lisheng Wang | 1,099,510 | 0.38% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 1,066,824 | 0.37% |